Illumina, Inc.
http://www.illumina.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Illumina, Inc.
Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
Spotting Zebras: Technology Cutting Through The Diagnostic Odyssey
In Vivo talked to two organizations making progress in the diagnosis of rare diseases using software and genomic sequencing.
Minute Insight: Hedera DX Completes €14m Raise To Fund ML-Backed Liquid Biopsy Tech
Hedera DX’s liquid biopsy test uses machine learning to recommend drugs to patients based on a tumor’s circulating DNA profile.
Deerfield Management On Fund Building, Philanthropy, And Optimism For The Future
Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.
Company Information
- Industry
- Pharmaceuticals
- Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- GenoLogics Life Sciences Software
- GRAIL Inc.
- Myraqa
- Verinata Health
- Illumina Ventures